Which new drugs for peripheral neuropathy received FDA fast-track or breakthrough designations in 2024–2025?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Two relevant regulatory moves in 2024–2025 implicate drugs and devices aimed at peripheral neuropathies, but only one — Sangamo’s investigational gene‑regulating candidate ST‑503 — is explicitly documented as having received an FDA Fast Track designation for a neuropathy indication; other high‑profile analgesic programs such as suzetrigine (VX‑548) earned Fast Track and Breakthrough Therapy designations for acute pain while having trial data in neuropathic conditions, a distinction that matters for claims about “neuropathy drugs” [1] [2] [3].
1. Sangamo’s ST‑503 — a clear Fast Track for small‑fiber neuropathy
Sangamo Therapeutics announced that the FDA granted Fast Track designation to ST‑503 for the treatment of intractable pain due to small fiber neuropathy (SFN), and the company reports ongoing Phase 1/2 STAND study enrollment and presentation of supportive nonclinical pharmacology and safety data [1]. That announcement explicitly ties the Fast Track status to a peripheral neuropathy subtype — SFN — and therefore stands as the clearest example in 2024–2025 of a new drug candidate receiving expedited FDA attention specifically for a neuropathy indication [1].
2. Suzetrigine (VX‑548) — breakthrough and Fast Track for acute pain, not formally for neuropathy
Suzetrigine, developed by Vertex (formerly VX‑548), received both Fast Track and Breakthrough Therapy designations from the FDA, but those regulatory labels were granted for moderate‑to‑severe acute pain rather than for chronic peripheral neuropathy as a formal indication; nevertheless, clinical trial programs included a phase 2 study in patients with painful diabetic neuropathy, and sponsors cite neuropathy data when describing the agent’s profile [2] [4] [3]. This creates an important nuance: suzetrigine’s regulatory advantages reflect potential broad utility in pain management, and while the program has evidence in neuropathic pain, the designations documented in available reporting were not explicitly for a neuropathy indication [2] [3].
3. Devices and other programs — clearance versus designation, and peripheral neuropathy mentions
A non‑drug technology, Neuralace Medical’s Axon Therapy, received FDA clearance as a noninvasive magnetic peripheral nerve stimulation system for painful diabetic neuropathy (PDN), but clearance under device pathways is not equivalent to Fast Track or Breakthrough Therapy designations that apply to drug development [5]. Industry trackers and consultancy summaries show multiple breakthrough grants in neuroscience and pain in 2024, including novel severe‑pain treatments such as ATX‑101 and PF614‑MPAR, but public summaries do not tie those particular breakthrough awards explicitly to peripheral neuropathy indications in the sources provided [6].
4. How FDA special‑designation categories shape interpretation
Fast Track and Breakthrough Therapy are distinct FDA tools intended to accelerate development and review for serious conditions with unmet needs; Fast Track encourages more frequent communication and rolling review possibilities, while Breakthrough status involves intensive FDA guidance and senior‑level involvement when preliminary clinical evidence indicates substantial improvement over existing therapies [7] [8]. Given those differences, a sponsor’s announcement that a program received Fast Track or Breakthrough status should be read against the exact indication the agency granted — a designation for “acute pain” may not legally equate to approval or expedited review for a specific neuropathy diagnosis [7] [8].
5. Takeaway and reporting limits
Based on available reporting, ST‑503 is the only program explicitly documented as receiving FDA Fast Track designation for a peripheral neuropathy diagnosis (small fiber neuropathy) in the 2024–2025 window [1]; suzetrigine’s Fast Track and Breakthrough labels reflect acute pain designations even though the drug has been studied in diabetic neuropathy [2] [3], and devices such as Axon Therapy achieved clearance rather than drug‑development designations [5]. There is no comprehensive official list in the supplied sources cataloguing every Fast Track/Breakthrough award for neuropathy across 2024–2025, so this analysis is confined to what the cited company and trade reports disclose [1] [2] [5] [6].